European Innovation Council

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

AlzeCure Pharma AB, established in 2012 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to developing drug therapies for central nervous system disorders. The company's primary focus is on Alzheimer's disease, with a pipeline consisting of five drug candidates based on its NeuroRestore and Alzstatin research platforms. These candidates are in various stages of development, targeting conditions such as sleep disruptions, traumatic brain injuries, neuropathic pain, and eye/ear indications. AlzeCure's team comprises key professionals with complementary expertise, spanning from molecule to man, and the company aims to be an industry-standard incubator for novel projects.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden, focused on developing innovative cell and gene therapies for cancer treatment. The company’s portfolio includes four drug candidates: ELC-100 and ELC-201, which are oncolytic virus therapies, and ELC-301 and ELC-401, which are CAR T-cell treatments. Additionally, Elicera has developed a universal CAR T-cell technology platform known as iTANK (ELC-001), designed to enhance the effectiveness of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors.

Aplagon is a biopharmaceutical company focused on developing innovative antithrombotic medications aimed at addressing complications associated with vascular interventions, particularly blood vessel occlusions. The company specializes in creating biological mimetics of heparin proteoglycan, which are intended for the clinical management of thrombotic occlusions and ischemic reperfusion injuries. Aplagon's mission is to provide patients with effective treatment options that offer significant safety advantages, thereby fulfilling unmet medical needs in the field of vascular health.

Hervolution Therapeutics focuses on developing first-in-class immunotherapies to combat tumors from within. The company leverages Human Endogenous Retroviral proteins (HERVs) to create rationally designed immune therapeutics targeting the dark genome. Hervolution Therapeutics aims to address hidden enemies within the human body by pioneering innovative biotechnology solutions.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

RS Research is a clinical-stage biotechnology company based in Istanbul, Turkey, focused on developing innovative nanomedicines for targeted cancer therapies. Founded in 2015, the company has established a proprietary drug delivery platform, Sagitta®, which enables the design of targeted drug candidates for various indications. RS Research's pipeline includes several proprietary programs in different stages of preclinical and clinical development, with its lead candidate, RS-0139, currently undergoing Phase I clinical trials in oncology patients. In addition to drug development, RS Research offers a range of services, including preclinical absorption, distribution, metabolism, and excretion studies, bioanalytical and analytical testing, and patent consulting. The company operates a GMP-certified production facility for clinical batch drug candidates and has successfully engaged in co-development projects with international partners, showcasing its commitment to advancing cancer treatment through modern therapeutic approaches.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

ResoTher Pharma is a Copenhagen-based biotechnology company specializing in the development of peptide-based drugs aimed at treating cardiovascular and inflammatory disorders characterized by neutrophil-driven inflammation. The company focuses on leveraging the endogenous immunomodulator Annexin A1 to create therapeutic solutions that act as resolution therapy for diseases associated with innate immune activation. By targeting a specific G-protein coupled receptor on leukocytes, ResoTher Pharma's patented peptide drugs aim to mimic the body's natural mechanisms for resolving inflammation and promoting tissue healing, addressing significant unmet medical needs in the treatment of these conditions.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

CarThera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices aimed at treating brain disorders. The company has created the SonoCloud®, an intracranial ultrasound implant that works in conjunction with a microbubble agent administered intravenously. This combination temporarily opens the blood-brain barrier, allowing for a significantly increased concentration of therapeutic molecules to penetrate the brain. By enhancing the delivery of treatments, CarThera's technology offers potential solutions for debilitating neurological conditions, providing healthcare professionals with new avenues for patient care.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Scandinavian Real Heart is a medical technology company focused on developing an innovative artificial heart designed to assist patients awaiting heart transplants. Their Total Artificial Heart (TAH) closely mimics the natural pumping mechanics, pressure ratios, and pulse of a healthy heart, aiming to provide improved functionality compared to existing options in the market. This device serves primarily as a transitional solution for individuals on the transplant waiting list, with the potential to save lives by addressing the urgent need for effective cardiac support.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

GrayMatters Health is a health technology company focused on developing digital therapeutics aimed at addressing mental disorders through the regulation of brain processes. By utilizing an approach grounded in neuroscience, the company provides solutions that enhance the efficacy, safety, and accessibility of mental healthcare. Their offerings empower healthcare professionals and patients alike, enabling individuals with neurological disorders to manage their conditions more effectively and conveniently. GrayMatters Health aims to bridge existing gaps in mental health treatment, promoting better outcomes for those affected by these challenges.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Valo Therapeutics is an immunotherapy company based in Oxford, United Kingdom, with an additional office in Helsinki, Finland. Founded in 2016, the company focuses on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Its primary platform, PeptiCRAd, is an engineered human oncolytic adenovirus designed to stimulate a systemic anti-tumor T cell response. This innovative approach enables the conversion of oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need for multiple genetically modified viruses. Additionally, Valo Therapeutics is working on other strategies, such as PeptiENV, to enhance therapeutic responses to enveloped oncolytic viruses across various cancer types. By utilizing tumor-specific peptides, the company aims to elicit a robust adaptive immune response, potentially providing lasting immunity against multiple cancers and improving patient outcomes.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

iLoF, or Intelligent Lab on Fiber, is a developer of a digital health platform that utilizes advanced photonics and artificial intelligence to enhance personalized drug discovery and development. The company has created a patented system that identifies and captures unique features of gold-standard biomarkers, compiling this information into a cloud-based library. By leveraging this extensive database, iLoF aims to facilitate collaboration among physicists, biologists, and data scientists, ultimately improving the efficiency and patient-centricity of clinical trials. This innovative approach not only reduces the costs associated with drug development but also aims to provide patients with tailored, life-saving treatments.

Arctic Therapeutics is a drug discovery and development company focused on identifying the genetic underpinnings of various diseases, both rare and common. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the significant risks and high costs associated with traditional drug development, thereby accelerating the process of bringing effective treatments to patients. Collaborating with The Center for Applied Genomics at the Children’s Hospital of Philadelphia, Arctic Therapeutics is engaged in repurposing and developing innovative medical treatments. The company’s pipeline, which includes a promising Alzheimer's drug candidate, is conservatively valued at over $100 billion, with the potential not only to treat dementia but also to prevent it. Arctic Therapeutics was founded by Dr. Hakon Hakonarson, a leading figure in applied genomics, known for his substantial contributions to the field, including the establishment of the largest pediatric biobank and genomic database globally. Dr. Hakonarson has received significant recognition for his research, which includes breakthroughs in autism genetics and precision-based therapies.

Arctic Therapeutics is a drug discovery and development company focused on identifying the genetic underpinnings of various diseases, both rare and common. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the significant risks and high costs associated with traditional drug development, thereby accelerating the process of bringing effective treatments to patients. Collaborating with The Center for Applied Genomics at the Children’s Hospital of Philadelphia, Arctic Therapeutics is engaged in repurposing and developing innovative medical treatments. The company’s pipeline, which includes a promising Alzheimer's drug candidate, is conservatively valued at over $100 billion, with the potential not only to treat dementia but also to prevent it. Arctic Therapeutics was founded by Dr. Hakon Hakonarson, a leading figure in applied genomics, known for his substantial contributions to the field, including the establishment of the largest pediatric biobank and genomic database globally. Dr. Hakonarson has received significant recognition for his research, which includes breakthroughs in autism genetics and precision-based therapies.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

NC Biomatrix is focused on developing medical therapies aimed at restoring the natural biomechanics of the spine to address low back pain. The company offers a non-invasive treatment option that involves an injectable viscous gel designed to alleviate the underlying causes of lower back pain. By targeting the biomechanics of the spine, NC Biomatrix provides a novel solution for patients suffering from osteoarthritis and related conditions, improving their quality of life through effective pain management.

Enduro Genetics is a technology provider that specializes in enhancing large-scale fermentations through its proprietary synthetic biology technology. The company focuses on improving the performance of fermentation processes by developing a genetic plugin technology that is free of antibiotic resistance genes. This innovation allows for higher yields by enriching spontaneous high producers within the fermentation population, facilitating the production of complex or cellular inhibit products by addressing strain instability. By maximizing the performance of cells derived from production strains, Enduro aims to bolster the competitiveness of both current and future green bioproduction initiatives.

ALA Diagnostics specializes in the development and marketing of in vitro diagnostic kits aimed at addressing high-prevalence pathologies and unmet medical needs. The company focuses particularly on multiple sclerosis, offering diagnostic kits that facilitate early diagnosis of the condition. These kits are designed for seamless integration into the clinical routines of hospitals and medical centers, enabling healthcare professionals to deliver accurate results. By improving diagnostic capabilities, ALA Diagnostics aims to enhance the quality of life for individuals affected by multiple sclerosis. The company leverages collaborations with public organizations to foster innovative projects and enhance its product offerings.

Gate2Brain is an early-stage biotech company dedicated to enhancing drug delivery across biological barriers, particularly the blood-brain barrier, through a patented peptide-based technology. This innovative platform aims to transport therapeutics directly to the brain, thereby improving the efficacy of treatments for neurological diseases and reducing associated side effects. Additionally, Gate2Brain focuses on developing therapeutics that can address rare pediatric cancers, positioning itself as a key player in advancing medical solutions for challenging conditions.

VIVAN Therapeutics is a company focused on transforming cancer care through personalized therapeutics. It utilizes a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, which enables the development of tailored treatment strategies. The company's approach involves the Personal Discovery Process (PDP), a unique clinical trial method designed for individual patients. This process analyzes the genetic complexity of each patient's tumor by engineering it into fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. VIVAN Therapeutics aims to provide less toxic and more affordable treatment options by recommending combinations of these drugs, thereby enhancing the effectiveness of cancer therapies. The company is also working on new diagnostics and decision support tools to improve treatment outcomes for cancer patients.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Xenikos is focused on developing innovative immunotherapy treatments aimed at addressing serious immune diseases and complications arising from transplants. The company specializes in anti-T-cell antibodies that can effectively reset the immune system. This therapeutic approach involves injecting a specific agent that targets and eliminates adult T cells, particularly those that are activated, thereby enhancing treatment outcomes for patients. By leveraging this unique mechanism, Xenikos seeks to restore health and improve the quality of life for individuals facing significant immune-related challenges.

Protinhi Therapeutics is a preclinical stage biotechnology company focused on developing antiviral drugs to combat various viral threats, including dengue, Zika, and COVID-19. The company's innovative approach utilizes proprietary technology and compounds that target viral diseases through protease inhibition. This mechanism disrupts the viruses' ability to replicate, providing healthcare providers with a means to effectively control the spread of these infections. By concentrating on significant public health challenges, Protinhi Therapeutics aims to contribute to global efforts in managing and mitigating viral outbreaks.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Meletios Therapeutics is a biotechnology company focused on developing antiviral molecules to address both current and emerging diseases. By targeting the host mechanisms that viruses exploit, the company aims to create antiviral drugs that empower healthcare institutions to effectively treat a variety of viral infections. Through its innovative approach, Meletios Therapeutics seeks to fulfill significant medical needs in the field of infectious diseases.

Meletios Therapeutics is a biotechnology company focused on developing antiviral molecules to address both current and emerging diseases. By targeting the host mechanisms that viruses exploit, the company aims to create antiviral drugs that empower healthcare institutions to effectively treat a variety of viral infections. Through its innovative approach, Meletios Therapeutics seeks to fulfill significant medical needs in the field of infectious diseases.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

ATXA Therapeutics Limited is a pharmaceutical company based in Dublin, Ireland, focused on developing novel small molecule drugs for the treatment of pulmonary arterial hypertension (PAH). Established in 2015 as a spin-out from University College Dublin, the company has leveraged over 20 years of research and more than €15 million in grant funding to advance its clinical trials and secure marketing authorization for its therapies. ATXA's innovative approach involves targeting human thromboxane receptors to enhance vasodilation and reduce vasoconstriction, addressing significant unmet medical needs in PAH and other cardiovascular conditions. The team comprises experts in various fields, including cardiovascular and cancer biology, drug discovery, and preclinical pharmacokinetics, positioning ATXA to develop more effective treatments than current standard care options. The company aims to improve treatment outcomes for patients suffering from PAH and related conditions through its advanced therapies.

ATXA Therapeutics Limited is a pharmaceutical company based in Dublin, Ireland, focused on developing novel small molecule drugs for the treatment of pulmonary arterial hypertension (PAH). Established in 2015 as a spin-out from University College Dublin, the company has leveraged over 20 years of research and more than €15 million in grant funding to advance its clinical trials and secure marketing authorization for its therapies. ATXA's innovative approach involves targeting human thromboxane receptors to enhance vasodilation and reduce vasoconstriction, addressing significant unmet medical needs in PAH and other cardiovascular conditions. The team comprises experts in various fields, including cardiovascular and cancer biology, drug discovery, and preclinical pharmacokinetics, positioning ATXA to develop more effective treatments than current standard care options. The company aims to improve treatment outcomes for patients suffering from PAH and related conditions through its advanced therapies.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Orixha specializes in the development of an innovative cooling device aimed at improving patient outcomes following cardiac arrest. This device utilizes a dedicated liquid ventilator that performs total liquid ventilation by filling the lungs with liquid perfluorocarbons. This method leverages the high gas solubility and large pulmonary surfaces to transform the lungs into an efficient heat exchange chamber with the bloodstream. By doing so, Orixha's technology helps protect vital organs from damage caused by reperfusion, thereby enhancing the prognosis for patients in critical conditions.

Protinhi Therapeutics is a preclinical stage biotechnology company focused on developing antiviral drugs to combat various viral threats, including dengue, Zika, and COVID-19. The company's innovative approach utilizes proprietary technology and compounds that target viral diseases through protease inhibition. This mechanism disrupts the viruses' ability to replicate, providing healthcare providers with a means to effectively control the spread of these infections. By concentrating on significant public health challenges, Protinhi Therapeutics aims to contribute to global efforts in managing and mitigating viral outbreaks.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Synergia Medical, established in 2013 and based in Mont-Saint-Guibert, Belgium, specializes in developing neurostimulation medical devices. The company is renowned for its innovative optoelectronic neurostimulator platform, which integrates biomaterials, optical components, biosensors, and microelectronics. Synergia's mission is to commercialize next-generation neurostimulation devices, led by a seasoned management team with extensive experience in developing implantable neurostimulators. In a short span of three years, the company achieved ISO13485 certification, created and sold an OEM external neurostimulator for a motorized amputee prosthesis arm, and developed its first version of the NAOS platform. Backed by private investors and public research grants, Synergia has grown to a team of thirteen highly skilled multidisciplinary professionals, focusing on advancing medical devices for neurostimulation using optoelectronics.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Orixha specializes in the development of an innovative cooling device aimed at improving patient outcomes following cardiac arrest. This device utilizes a dedicated liquid ventilator that performs total liquid ventilation by filling the lungs with liquid perfluorocarbons. This method leverages the high gas solubility and large pulmonary surfaces to transform the lungs into an efficient heat exchange chamber with the bloodstream. By doing so, Orixha's technology helps protect vital organs from damage caused by reperfusion, thereby enhancing the prognosis for patients in critical conditions.

AuriGen Medical Limited is an electrophysiology and structural heart company based in Dublin, Ireland, founded in 2016. The company focuses on developing innovative left atrial appendage (LAA) implants designed to address the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). AuriGen's technology targets highly symptomatic patients who are resistant to medication, a demographic that includes over 3 million individuals in the United States and Europe. The rising incidence of AF, particularly among aging populations, underscores the urgent need for effective treatment alternatives. AuriGen's devices incorporate custom LAA occluder implants and are designed to enhance patient outcomes by reducing reliance on anticoagulants and anti-arrhythmic medications. With the annual costs of managing medication-resistant AF running into billions, AuriGen aims to provide cost-effective solutions that improve treatment efficacy and patient quality of life.

Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Hy2Care BV is a start-up based at the University of Twente in the Netherlands, focused on developing a groundbreaking treatment for osteoarthritis, a condition affecting over 100 million patients in the Western world. The company's primary product is an injectable hydrogel, designed to repair cartilage defects, particularly in the knee. This bioresorbable hydrogel consists of a two-component system made from natural polymer conjugates that undergo a mild enzymatic reaction to create a functional repair solution for cartilage damage. Hy2Care aims to significantly improve the quality of life for individuals suffering from osteoarthritis by providing an effective and innovative treatment option.

Loci Orthopaedics Limited, based in Upper Newcastle, Ireland, specializes in developing innovative medical technologies to address significant unmet clinical needs in orthopedics. Founded in 2017, the company focuses on creating surgical implants, particularly the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, offering a less invasive and easier insertion method compared to existing surgical options. Additionally, Loci Orthopaedics is known for its Osteoanchor surface architecture, which is based on evidence-based designs, enabling clinicians to effectively address challenges in orthopedic extremities.

Loci Orthopaedics Limited, based in Upper Newcastle, Ireland, specializes in developing innovative medical technologies to address significant unmet clinical needs in orthopedics. Founded in 2017, the company focuses on creating surgical implants, particularly the InDx implant, which is designed to treat arthritis in the thumb base joint. This implant uniquely mimics the natural motions of the thumb joint, offering a less invasive and easier insertion method compared to existing surgical options. Additionally, Loci Orthopaedics is known for its Osteoanchor surface architecture, which is based on evidence-based designs, enabling clinicians to effectively address challenges in orthopedic extremities.

Hy2Care BV is a start-up based at the University of Twente in the Netherlands, focused on developing a groundbreaking treatment for osteoarthritis, a condition affecting over 100 million patients in the Western world. The company's primary product is an injectable hydrogel, designed to repair cartilage defects, particularly in the knee. This bioresorbable hydrogel consists of a two-component system made from natural polymer conjugates that undergo a mild enzymatic reaction to create a functional repair solution for cartilage damage. Hy2Care aims to significantly improve the quality of life for individuals suffering from osteoarthritis by providing an effective and innovative treatment option.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden, focused on developing innovative cell and gene therapies for cancer treatment. The company’s portfolio includes four drug candidates: ELC-100 and ELC-201, which are oncolytic virus therapies, and ELC-301 and ELC-401, which are CAR T-cell treatments. Additionally, Elicera has developed a universal CAR T-cell technology platform known as iTANK (ELC-001), designed to enhance the effectiveness of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors.

Artiria Medical SA develops innovative micro-actuated devices aimed at treating vascular diseases, particularly in the brain. Founded in 2019 and based in Lausanne, Switzerland, the company focuses on enhancing the precision and control of surgical procedures involving catheters and guidewires. Its technology facilitates micromotion within brain arteries, thereby improving navigation during stroke treatments. By enabling surgeons to perform these complex procedures with greater accuracy, Artiria Medical contributes to better patient outcomes and the potential to save lives.

Aplagon is a biopharmaceutical company focused on developing innovative antithrombotic medications aimed at addressing complications associated with vascular interventions, particularly blood vessel occlusions. The company specializes in creating biological mimetics of heparin proteoglycan, which are intended for the clinical management of thrombotic occlusions and ischemic reperfusion injuries. Aplagon's mission is to provide patients with effective treatment options that offer significant safety advantages, thereby fulfilling unmet medical needs in the field of vascular health.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Aplagon is a biopharmaceutical company focused on developing innovative antithrombotic medications aimed at addressing complications associated with vascular interventions, particularly blood vessel occlusions. The company specializes in creating biological mimetics of heparin proteoglycan, which are intended for the clinical management of thrombotic occlusions and ischemic reperfusion injuries. Aplagon's mission is to provide patients with effective treatment options that offer significant safety advantages, thereby fulfilling unmet medical needs in the field of vascular health.

NeuoKaire, previously known as Genetika+, is focused on advancing personalized medical testing for the treatment of depression. The company has developed a platform that utilizes biological, medical, and genetic data, along with innovative technology, to identify the most effective drug therapies for individual patients. This approach aims to facilitate faster treatment, minimize side effects, and reduce dosages. By assisting pharmaceutical companies in differentiating their products and de-risking clinical trials, NeuoKaire enhances the identification of responsive patients and improves stratification. The integration of stem-cell technology, genomics, and artificial intelligence further supports the optimization of treatments for psychiatric and neurological disorders, ultimately aiming to transform care and improve patient outcomes.

BrainEver focuses on developing innovative therapeutics for neurodegenerative disorders, rooted in the research of Alain Prochiantz and colleagues on brain development and physiology. The company explores the potential of homeoproteins, which are known to regulate neuronal functions throughout life, to enhance the physiological resistance and activity of surviving neurons in patients. This approach aims to improve clinical symptoms in conditions such as Parkinson's disease and amyotrophic lateral sclerosis (ALS). The company is advancing its lead candidate, Engrailed 1 (BREN01), while also working on a pipeline of additional drug candidates targeting other neurodegenerative diseases, including Huntington's disease and optic neuropathies. By developing these novel therapeutics, BrainEver aims to provide effective treatment options for healthcare practitioners and patients affected by these challenging conditions.

Scandinavian Real Heart is a medical technology company focused on developing an innovative artificial heart designed to assist patients awaiting heart transplants. Their Total Artificial Heart (TAH) closely mimics the natural pumping mechanics, pressure ratios, and pulse of a healthy heart, aiming to provide improved functionality compared to existing options in the market. This device serves primarily as a transitional solution for individuals on the transplant waiting list, with the potential to save lives by addressing the urgent need for effective cardiac support.

Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.

GrayMatters Health is a health technology company focused on developing digital therapeutics aimed at addressing mental disorders through the regulation of brain processes. By utilizing an approach grounded in neuroscience, the company provides solutions that enhance the efficacy, safety, and accessibility of mental healthcare. Their offerings empower healthcare professionals and patients alike, enabling individuals with neurological disorders to manage their conditions more effectively and conveniently. GrayMatters Health aims to bridge existing gaps in mental health treatment, promoting better outcomes for those affected by these challenges.

Askel Healthcare is a medical device company focused on improving knee cartilage repair and recovery. The company offers a science-backed solution designed to rebuild the knee joint surface, facilitating a quicker return to an active and pain-free life. Its innovative device provides evidence-based solutions that address cartilage repair and the prevention of osteoarthritis, not only in human medicine but also in veterinary applications. This dual approach enables healthcare providers to treat a larger number of patients efficiently while minimizing complications and reducing costs, ultimately fostering faster rehabilitation.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.

EVerZom is a nanomedicine biotech company based in Paris, France, specializing in the large-scale manufacturing of extracellular vesicles. Founded in 2019, the company has developed a unique, GMP-compliant bioproduction platform aimed at pharmaceutical companies. This platform enables the production of various types of extracellular vesicles, including exosomes, microvesicles, and apoptotic bodies, which are essential for intercellular communication. EVerZom's products possess protective and reparative properties, making them valuable therapeutic tools in regenerative medicine and drug delivery. The company's technology is designed to assist healthcare professionals in addressing organ failure and restoring function and homeostasis.

Healium Medical Ltd, founded in 2017 and based in Yokneam, Israel, specializes in developing a non-contact guided ultrasound ablation system aimed at treating atrial fibrillation. The company offers an innovative approach to pulmonary vein isolation by utilizing a proprietary ultrasound transducer that allows for rapid, circumferential ablation without direct contact with the tissue. This system features integrated real-time lesion monitoring, enhancing the effectiveness and efficiency of the procedure while simplifying its flow and reducing overall time. Healium Medical is part of Alon MedTech Ventures, which supports the growth of high-tech medical device companies focused on improving health outcomes and quality of life.

Healium Medical Ltd, founded in 2017 and based in Yokneam, Israel, specializes in developing a non-contact guided ultrasound ablation system aimed at treating atrial fibrillation. The company offers an innovative approach to pulmonary vein isolation by utilizing a proprietary ultrasound transducer that allows for rapid, circumferential ablation without direct contact with the tissue. This system features integrated real-time lesion monitoring, enhancing the effectiveness and efficiency of the procedure while simplifying its flow and reducing overall time. Healium Medical is part of Alon MedTech Ventures, which supports the growth of high-tech medical device companies focused on improving health outcomes and quality of life.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Allero Therapeutics B.V. is a biopharmaceutical company based in Rotterdam, the Netherlands, founded in 2016. The company specializes in developing programmed immunotherapies aimed at treating immune-mediated disorders. Utilizing its Specific Oromucosal Immunotherapy (SOMIT) platform, Allero Therapeutics focuses on restoring immune tolerance through the targeted delivery of antigen-specific therapies. This innovative approach is based on research conducted by the founders and their collaborators, enabling the induction of long-lasting antigen-specific tolerance. The technology is designed to address a variety of clinical indications with significant unmet medical needs, particularly in the fields of allergic and autoimmune diseases.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

GrayMatters Health is a health technology company focused on developing digital therapeutics aimed at addressing mental disorders through the regulation of brain processes. By utilizing an approach grounded in neuroscience, the company provides solutions that enhance the efficacy, safety, and accessibility of mental healthcare. Their offerings empower healthcare professionals and patients alike, enabling individuals with neurological disorders to manage their conditions more effectively and conveniently. GrayMatters Health aims to bridge existing gaps in mental health treatment, promoting better outcomes for those affected by these challenges.

Genome Biologics specializes in therapeutic target discovery and RNA-targeted therapies, focusing on cardiovascular and cardiometabolic diseases. The company employs an innovative biotherapeutics platform that integrates AI-based machine learning with advanced single-cell transgenesis techniques to enhance drug development. This approach allows for the identification of new compounds and the repurposing of existing drugs, ultimately facilitating more efficient and ethical preclinical research. By addressing conditions where traditional treatments are ineffective or nonexistent, Genome Biologics aims to reduce the cost and duration of drug development while minimizing the ethical challenges associated with medical research.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Fibriant is a biotechnology startup dedicated to the development and production of recombinant fibrinogen, a critical protein in blood that facilitates clotting and supports tissue repair and immune responses. The company operates a platform that produces flexible and biodegradable fibrinogen variants, which are designed to enhance processes such as wound healing and tissue remodeling. Fibriant's products aim to assist healthcare organizations in preventing complications, such as early and late-stage vein graft failure following bypass surgery, thereby improving patient outcomes in various medical applications.

Op2Lysis is a company focused on developing a neurotic drug aimed at treating hemorrhagic strokes. Its primary product is a thrombolytic agent designed to dissolve the intracerebral hematoma that develops after such strokes. This innovative treatment can be administered locally through a catheter, utilizing micro-invasive surgical techniques. By effectively liquefying the hematoma, Op2Lysis's therapy aims to help patients avoid significant disabilities and the need for extensive surgical procedures.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.